VIDEO: Pancreatic cancer trial results show ‘we have to move in a different direction’
In this video, Michael Cecchini, MD, discusses results of two clinical trials evaluating pamrevlumab in pancreatic cancer, which were presented at ASCO Gastrointestinal Cancers Symposium.
The double-blind, placebo-controlled phase 3 LAPIS trial evaluated the safety and efficacy of pamrevlumab (FibroGen) plus chemotherapy in patients with unresectable locally advanced pancreatic cancer.
The phase 2/3 Precision Promise Bayesian platform trial examined pamrevlumab plus nab-paclitaxel/gemcitabine as first- and second-line therapy for metastatic pancreatic cancer vs. combination chemotherapy.
“While we had very promising phase 1 and phase 2 data to get us to [this] point, pamrevlumab did not show a signal for benefit in those confirmatory studies,” Cecchini, associate professor of medical oncology at Yale School of Medicine, said. “[It is] very important to have this data to understand that we have to move in a different direction in this disease and try different agents, and not … lose the momentum that the field has for treating pancreas cancer.”
References:
- Picozzi VJ, et al. Abstract 675. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 23-25, 2025; San Francisco.
- Picozzi VJ, et al. Abstract 673. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 23-25, 2025; San Francisco.
Collapse